MCID: HMN044
MIFTS: 70

Human Immunodeficiency Virus Type 1

Categories: Genetic diseases, Immune diseases

Aliases & Classifications for Human Immunodeficiency Virus Type 1

MalaCards integrated aliases for Human Immunodeficiency Virus Type 1:

Name: Human Immunodeficiency Virus Type 1 57
Hiv/aids 57 38 43 3
Aids 57 76 55 3
Human Immunodeficiency Virus Type 1, Susceptibility to 57 29 6
Aids, Delayed/rapid Progression to 57 13 6
Hiv-1 Viremia, Susceptibility to 57 6
Hiv1 Infection 57 38
Hiv-1 57 38
Rapid Progression to Aids from Hiv1 Infection 57
Human Immunodeficiency Virus I Infection 73
Acquired Immunodeficiency Syndrome 73
Hiv1 Infection, Resistance to 57
Hiv Type 1, Susceptibility to 57
Hiv Infection, Resistance to 57
Hiv/aids, Susceptibility to 57
Aids, Rapid Progression to 57
Aids, Slow Progression to 57
Hiv-1, Susceptibility to 57
Hiv-1, Resistance to 57
Aids, Resistance to 57
Hiv1, Resistance to 57
Hiv-Infection/aids 73
Hiv-1 Viremia 57
Hiv Type 1 57
Hiv1 57

Classifications:



External Ids:

OMIM 57 609423

Summaries for Human Immunodeficiency Virus Type 1

MedlinePlus : 43 HIV stands for human immunodeficiency virus. It harms your immune system by destroying the white blood cells that fight infection. This puts you at risk for serious infections and certain cancers. AIDS stands for acquired immunodeficiency syndrome. It is the final stage of infection with HIV. Not everyone with HIV develops AIDS. HIV most often spreads through unprotected sex with an infected person. It may also spread by sharing drug needles or through contact with the blood of an infected person. Women can give it to their babies during pregnancy or childbirth. The first signs of HIV infection may be swollen glands and flu-like symptoms. These may come and go within two to four weeks. Severe symptoms may not appear until months or years later. A blood test can tell if you have HIV infection. Your health care provider can do the test, or you can use a home testing kit. Or to find free testing sites, call the national referral hotline at 1-800-CDC-INFO (1-800-232-4636 in English and en español; 1-888-232-6348 - TTY). There is no cure, but there are many medicines that fight HIV infection and lower the risk of infecting others. People who get early treatment can live with the disease for a long time. Strategies to reduce the risk of HIV infection include not having sex, limiting your number of sexual partners, never sharing needles, and using condoms the right way every time you have sex. People who are at high risk may take HIV prevention medicines.

MalaCards based summary : Human Immunodeficiency Virus Type 1, also known as hiv/aids, is related to encephalitis and acquired immunodeficiency syndrome, and has symptoms including fever and pruritus. An important gene associated with Human Immunodeficiency Virus Type 1 is KIR3DL1 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Dolutegravir and Maraviroc have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and bone, and related phenotypes are hematopoietic system and immune system

OMIM : 57 The pathogenesis of HIV infection and the progression from infection to AIDS vary significantly between exposed individuals. Infection occurs after the virus, which has macrophage (M)- and T lymphocyte (T)-tropic strains and more than 12 subtypes, survives an array of nonspecific, nongenetic environmental and host factors. (609423)

CDC : 3 Help

Wikipedia : 76 Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS) is a spectrum... more...

Related Diseases for Human Immunodeficiency Virus Type 1

Diseases related to Human Immunodeficiency Virus Type 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 175)
# Related Disease Score Top Affiliating Genes
1 encephalitis 32.4 CCL2 CCR5 CD209 TLR3
2 acquired immunodeficiency syndrome 32.3 CCL3 CCR2 CCR5 IFNG IL10 ITIH4
3 schistosomiasis 32.0 CCL3 IFNG IL10
4 cytomegalovirus retinitis 32.0 CCR2 CCR5 CD9 IFNG
5 cytomegalovirus infection 31.9 IFNG IL10 KIR3DL1
6 pulmonary tuberculosis 31.9 CCL3 IFNG IL10
7 meningitis 31.9 CCL2 IFNG IL10
8 lymphadenitis 31.8 CD209 IFNG IL10
9 west nile virus 31.7 CCR5 CD209 TLR3
10 measles 31.4 CD209 IFNG TLR3
11 vulvovaginitis 30.3 CCL11 IL10
12 human immunodeficiency virus infectious disease 11.6 CCL3 CCR2 CCR5 CXCL12 IFNG IL10
13 immune deficiency disease 11.6 CCR5 CXCL12 IFNG IL10 ITIH4
14 orofacial granulomatosis 11.6 CCL3 CCR5 IFNG IL10
15 viral infectious disease 11.6 CCL3 CCR5 CD209 IFNG IL10 ITIH4
16 chagas disease 11.5 CCL2 CCL3 CCR5 IFNG IL10
17 mucocutaneous leishmaniasis 11.5 CCR5 IL10 TLR3
18 polyradiculoneuropathy 11.5 CXCL12 IFNG IL10
19 variola major 11.5 CCL3 IFNG TLR3
20 tick-borne encephalitis 11.5 CCR5 CD209 IL10 TLR3
21 trypanosomiasis 11.5 CCL2 CCL3 IFNG IL10
22 secondary progressive multiple sclerosis 11.5 CCL2 CCR2 CCR5 IL10
23 demyelinating disease 11.5 CCL2 CCL3 IFNG IL10
24 hemorrhagic fever 11.5 CD209 IFNG IL10
25 rheumatoid arthritis 11.5 CCL2 CCL3 CCR2 CXCL12 IFNG IL10
26 multiple sclerosis 11.5 CCL2 CCL3 CCR5 IFNG IL10
27 dengue hemorrhagic fever 11.4 CD209 IFNG IL10
28 toxoplasmosis 11.4 CCR5 IFNG IL10
29 chronic nk-cell lymphocytosis 11.4 CCL3 CCR5 CXCR1
30 leprosy 3 11.4 CD209 IFNG IL10
31 extrapulmonary tuberculosis 11.4 CCL2 IFNG IL10
32 spondyloarthropathy 11.4 HLA-C IFNG IL10
33 bronchiolitis 11.4 CCL11 CCL3 IFNG IL10 IL4R
34 pulmonary fibrosis, idiopathic 11.4 CCL2 CCL3 CXCL12 CXCR1 IFNG
35 behcet syndrome 11.4 CCL3 CCR5 HLA-C IFNG IL10 KIR3DL1
36 retinal vasculitis 11.4 CCL2 CX3CR1 TLR3
37 ige responsiveness, atopic 11.4 IFNG IL10 IL4R
38 pulmonary sarcoidosis 11.4 CCL2 CCR5 IFNG
39 aspergillosis 11.4 CD209 IFNG IL10
40 extrinsic cardiomyopathy 11.4 CCL2 IL10 TLR3
41 hyperlucent lung 11.4 IFNG IL10
42 allergic hypersensitivity disease 11.4 CCL11 IFNG IL10 IL4R
43 idiopathic bronchiectasis 11.4 CXCR1 HLA-C IFNG
44 allergic asthma 11.4 CCL11 IFNG IL10 IL4R
45 severe acute respiratory syndrome 11.4 CCL2 CD209 IFNG
46 autoinflammation, lipodystrophy, and dermatosis syndrome 11.4 CCL11 CCL2 CCL3 IFNG IL10
47 bone inflammation disease 11.4 CCL2 IFNG IL10
48 graft-versus-host disease 11.4 HLA-C IFNG IL10
49 hematopoietic stem cell transplantation 11.4 HLA-C IFNG IL10 KIR3DL1
50 whiplash 11.4 CCL3 CCR5

Graphical network of the top 20 diseases related to Human Immunodeficiency Virus Type 1:



Diseases related to Human Immunodeficiency Virus Type 1

Symptoms & Phenotypes for Human Immunodeficiency Virus Type 1

Clinical features from OMIM:

609423

UMLS symptoms related to Human Immunodeficiency Virus Type 1:


fever, pruritus

MGI Mouse Phenotypes related to Human Immunodeficiency Virus Type 1:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.1 CCR5 CD9 CX3CR1 CXCL12 CXCR1 IFNG
2 immune system MP:0005387 10.07 CCL11 CCL2 CCR2 CCR5 CD9 CX3CR1
3 liver/biliary system MP:0005370 9.7 CCR2 CCR5 CXCL12 IFNG IL10 IL4R
4 neoplasm MP:0002006 9.43 ITIH4 TLR3 CCR2 CCR5 IFNG IL10
5 respiratory system MP:0005388 9.17 CCL11 CCR2 CD9 IFNG IL10 IL4R

Drugs & Therapeutics for Human Immunodeficiency Virus Type 1

Drugs for Human Immunodeficiency Virus Type 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 586)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Dolutegravir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1051375-16-6 54726191
2
Maraviroc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 376348-65-1 3002977
3
Darunavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 635728-49-3, 206361-99-1 213039
4
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 155213-67-5 392622
5
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Not Applicable 128794-94-5 5281078
6
Mycophenolic acid Approved Phase 4,Phase 3,Not Applicable 24280-93-1 446541
7
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 143491-57-0 60877
8
Zidovudine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 30516-87-1 35370
9
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 154598-52-4 64139
10
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134678-17-4 60825
11
Lopinavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 192725-17-0 92727
12
Cobicistat Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1004316-88-4
13
Rilpivirine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 500287-72-9
14
Didanosine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 69655-05-6 50599
15
Nelfinavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159989-64-7 64143
16
Stavudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3056-17-5 18283
17
Abacavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 136470-78-5 65140 441300
18
Amprenavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 161814-49-9 65016
19
Rifabutin Approved, Investigational Phase 4,Phase 2,Phase 1 72559-06-9 6323490
20
Nevirapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129618-40-2 4463
21
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
22
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 36791-04-5 37542
23
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 93-14-1 3516
24
Methadone Approved Phase 4,Phase 1,Not Applicable 76-99-3 4095
25
Enfuvirtide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 159519-65-0 16130199
26
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 198153-51-4 5360545
27
Fosamprenavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 226700-79-4 131536
28
Indinavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 150378-17-9 5362440
29
Rifampicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 13292-46-1 5458213 5381226
30
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 1,Phase 2 99210-65-8, 215647-85-1
31
Tipranavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174484-41-4 65027
32
Acyclovir Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 59277-89-3 2022
33
Etravirine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 269055-15-4 193962
34
Atovaquone Approved Phase 4 95233-18-4 74989
35
Proguanil Approved Phase 4 500-92-5 4923
36
Saquinavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 127779-20-8 60787
37
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
38
Angiotensin II Approved, Investigational Phase 4,Phase 2,Phase 1 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
39
Losartan Approved Phase 4,Phase 2 114798-26-4 3961
40
Zalcitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 7481-89-2 24066
41
Hydroxyurea Approved Phase 4,Phase 2,Phase 1,Not Applicable 127-07-1 3657
42
Sorbitol Approved Phase 4 50-70-4 5780
43
Bleomycin Approved, Investigational Phase 4,Phase 3 11056-06-7 5360373
44
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 1 23214-92-8 31703
45
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
46
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 1 53-03-2 5865
47
Ethambutol Approved Phase 4,Phase 2,Phase 3 74-55-5 3279 14052
48
Isoniazid Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 54-85-3 3767
49
Pyrazinamide Approved, Investigational Phase 4,Phase 2,Phase 3 98-96-4 1046
50
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52485-79-7 40400 644073

Interventional clinical trials:

(show top 50) (show all 2154)
# Name Status NCT ID Phase Drugs
1 A Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication Unknown status NCT00840762 Phase 4
2 Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients Unknown status NCT02370979 Phase 4
3 Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3 Unknown status NCT01235013 Phase 4 Maraviroc
4 Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients Unknown status NCT01013987 Phase 4 maraviroc;Raltegravir;Darunavir/ritonavir
5 Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese Patients Unknown status NCT01201239 Phase 4 raltegravir
6 Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients Unknown status NCT00247494 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
7 Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients Unknown status NCT01017172 Phase 4
8 A Pilot Study of Triple NtRTI/NsRTI Therapy in Antiretroviral Naive HIV-1 Infected Patients Unknown status NCT00199121 Phase 4 Zidovudine (drug)
9 Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study) Unknown status NCT00120419 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
10 PI Vs. NNRTI Based Therapy for HIV Advanced Disease Unknown status NCT00162643 Phase 4 zidovudine+lamivudine+lopinavir/ritonavir;zidovudine + lamivudine + efavirenz
11 Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects Unknown status NCT02404233 Phase 4 darunavir/cobicistat;rilpivirine
12 Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs Unknown status NCT00005000 Phase 4 Nelfinavir mesylate;Efavirenz;Lamivudine;Keyhole-Limpet Hemocyanin;Stavudine;Zidovudine;Didanosine
13 Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment Unknown status NCT00005017 Phase 4 Ritonavir;Abacavir sulfate;Amprenavir;Efavirenz;Lamivudine;Stavudine
14 Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs Unknown status NCT00011895 Phase 4 Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
15 Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT) Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
16 SHARE: Simple HAART With Abacavir, Reyataz, and Epivir Unknown status NCT00426296 Phase 4 atazanavir (Reyataz);ritonavir (Norvir)
17 Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients Unknown status NCT01059422 Phase 4 Raltegravir; Abacavir/Lamivudine
18 MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) Unknown status NCT00122226 Phase 4 Lopinavir/ritonavir + zidovudine + lamivudine;Lopinavir/ritonavir + nevirapine
19 Computerized Counseling to Promote Positive Prevention and HIV Health in Kenya Unknown status NCT01015989 Phase 4
20 Efavirenz to Dolutegravir Switch in Patients With CNS Toxicity Unknown status NCT02285374 Phase 4 Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir
21 Maraviroc Abacavir STudy - Effect on Endothelial Recovery Unknown status NCT01389063 Phase 4 Maraviroc
22 Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients Unknown status NCT02008214 Phase 4 Pentoxifylline;Placebo
23 Simplification From Protease Inhibitors to Raltegravir Unknown status NCT00941083 Phase 4 Raltegravir (Use RAL as a simplification strategy);Raltegravir (Use RAL as a simplification strategy);Raltegravir (Use RAL as a simplification strategy)
24 Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
25 Once Daily 3TC, Efavirenz and ddI for HIV Infection Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
26 Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts Completed NCT01928407 Phase 4 DARUNAVIR;ATAZANAVIR
27 Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla Completed NCT02547844 Phase 4 efavirenz + emtricitabina + tenofovir;rilpivirina + emtricitabina + tenofovir
28 Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 Patients Completed NCT01702090 Phase 4 TMC114/ritonavir
29 Valacyclovir vs. Acyclovir as HSV-2 Suppressive Therapy: Effect on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons Completed NCT01026454 Phase 4 acyclovir;valacyclovir
30 BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Completed NCT00326963 Phase 4 Background ARVs;PI;enfuvirtide [Fuzeon]
31 Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1—Infected Patients Completed NCT01332227 Phase 4 Atazanavir;Ritonavir (heat-stable);Raltegravir;Tenofovir/Emtricitabine
32 Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada Completed NCT00324649 Phase 4 Truvada;Zidovudine/lamivudine
33 Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients Completed NCT01989910 Phase 4 Raltegravir;Efavirenz
34 Safety and Efficacy Study of Switching From Epzicom to Truvada Completed NCT00724711 Phase 4 emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF);abacavir (ABC)/lamivudine (3TC)
35 HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain Completed NCT00685191 Phase 4 Salvage antiretroviral therapy including raltegravir
36 Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients Completed NCT00106379 Phase 4 Truvada (tenofovir DF + emtricitabine);Emtriva (emtricitabine);Viread (tenofovir DF)
37 A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE) Completed NCT01102972 Phase 4 Reyataz + Norvir + Truvada;Reyataz + Epzicom
38 Study to Compare the Virologic Efficacy in Cerebrospinal Fluid (CSF) and Neurocognitive State in Patients Infected by HIV-1 Long-term Treatment (> 3 Years) With Lopinavir / Ritonavir Monotherapy Completed NCT01116817 Phase 4
39 Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults Completed NCT02246998 Phase 4 STB;TVD;ATR;RTV;ATV;ABC/3TC;Iohexol
40 Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients Completed NCT00365612 Phase 4 Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF)
41 Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV Completed NCT00527618 Phase 4 valacyclovir;acyclovir
42 ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial Completed NCT00772902 Phase 4 Truvada + Kaletra;Kivexa + Kaletra
43 Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infected Patients Completed NCT00441688 Phase 4 GI265235
44 Maraviroc in Immunological Non-Responder (INR) HIV-1-infected Subjects Completed NCT00884858 Phase 4 Maraviroc
45 Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected Patients Completed NCT01274780 Phase 4 Darunavir / Ritonavir + Tenofovir / Emtricitabine;Atazanavir / Ritonavir + Tenofovir / Emtricitabine
46 A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients Completed NCT01422330 Phase 4 Etravirine
47 ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla Completed NCT00615745 Phase 4 Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg
48 Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients Completed NCT00287677 Phase 4 HAART
49 Genotypic Tropism Testing In Proviral Dna To Guide CCR5 Antagonist Treatment In Subjects With Undetectable HIV-1 Viremia Completed NCT01378910 Phase 4 Unique
50 A Phase IV, Open-label Single-arm Study Investigating the Pharmacokinetics and Pharmacodynamics of the Antiretroviral Combination of Rilpivirine and Ritonavirboosted Darunavir in Therapy-naive HIV-1 Infected Patients. Completed NCT01736761 Phase 4 Darunavir, Ritonavir and Rilpivirine

Search NIH Clinical Center for Human Immunodeficiency Virus Type 1

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Human Immunodeficiency Virus Type 1 cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Human Immunodeficiency Virus Type 1:
AGS-004, electroporated mature dendritic cells for HIV
Embryonic/Adult Cultured Cells Related to Human Immunodeficiency Virus Type 1:
Maturated and electroporated dendritic cells PMIDs: 20636001

Genetic Tests for Human Immunodeficiency Virus Type 1

Genetic tests related to Human Immunodeficiency Virus Type 1:

# Genetic test Affiliating Genes
1 Human Immunodeficiency Virus Type 1, Susceptibility to 29 CCL11 CCL2 CCL3 CCL3L1 CD209 CX3CR1 CXCL12 CXCR1 HLA-C IFNG IL10 IL4R KIR3DL1 TLR3

Anatomical Context for Human Immunodeficiency Virus Type 1

MalaCards organs/tissues related to Human Immunodeficiency Virus Type 1:

41
Testes, T Cells, Bone, Monocytes, Brain, Liver, Kidney

Publications for Human Immunodeficiency Virus Type 1

Articles related to Human Immunodeficiency Virus Type 1:

(show top 50) (show all 2345)
# Title Authors Year
1
Human immunodeficiency virus type 1 (HIV-1)-mediated neuroinflammation dysregulates neurogranin and induces synaptodendritic injury. ( 29703241 )
2018
2
Immunogenetic factors in early immune control of human immunodeficiency virus type 1 (HIV-1) infection: Evaluation of HLA class I amino acid variants in two African populations. ( 29289742 )
2018
3
Molecular identification of tick-borne pathogens in asymptomatic individuals with human immunodeficiency virus type 1 (HIV-1) infection: a retrospective study. ( 29776392 )
2018
4
Phylogenetic and temporal dynamics of human immunodeficiency virus type 1 CRF01_AE and CRF07_BC among recently infected antiretroviral therapy-naA^ve men who have sex with men in Jiangsu province, China, 2012 to 2015: A molecular epidemiology-based study. ( 29419684 )
2018
5
Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. ( 29437967 )
2018
6
Expression of Human Immunodeficiency Virus type 1 (HIV-1) coat protein genes in plants using cotton leaf curl Multan betasatellite-based vector. ( 29304063 )
2018
7
In vitro basal T-cell proliferation among asymptomatic Human T cell Leukemia Virus type 1 patients co-infected with hepatitis C and/or Human Immunodeficiency Virus type 1. ( 29499169 )
2018
8
Inclusion body myositis and human immunodeficiency virus type 1: A new case report and literature review. ( 29426734 )
2018
9
Context-dependent autoprocessing of human immunodeficiency virus type 1 protease precursors. ( 29338056 )
2018
10
Experimental Adaptive Evolution of Simian Immunodeficiency Virus SIVcpz to Pandemic Human Immunodeficiency Virus Type 1 by Using a Humanized Mouse Model. ( 29212937 )
2018
11
Nonreactive Human Immunodeficiency Virus Type 1 Rapid Tests After Sustained Viral Suppression Following Antiretroviral Therapy Initiation During Primary Infection. ( 29509924 )
2018
12
Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine. ( 29636755 )
2018
13
Genotypic Characterization of Human Immunodeficiency Virus Type 1 Prevalent in Kepulauan Riau, Indonesia. ( 29589465 )
2018
14
Analysis of Select Herpes Simplex Virus 1 (HSV-1) Proteins for Restriction of Human Immunodeficiency Virus Type 1 (HIV-1): HSV-1 gM Protein Potently Restricts HIV-1 by Preventing Intracellular Transport and Processing of Env gp160. ( 29093081 )
2018
15
Identification of a Conserved Interface of Human Immunodeficiency Virus Type 1 and Feline Immunodeficiency Virus Vifs with Cullin 5. ( 29263270 )
2018
16
Acquisition of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Infection in a Patient Taking Preexposure Prophylaxis. ( 29961859 )
2018
17
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and its Phosphonooxymethyl Prodrug Fostemsavir. ( 29920093 )
2018
18
Human Immune System Mice for the Study of Human Immunodeficiency Virus-Type 1 Infection of the Central Nervous System. ( 29670623 )
2018
19
Indolylarylsulfones, a fascinating story of highly potent human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors. ( 29417826 )
2018
20
Trametinib suppresses HIV-1 replication by interfering with the disassembly of human immunodeficiency virus type 1 capsid core. ( 29197575 )
2018
21
Quercetin synergistically reactivates human immunodeficiency virus type 1 latency by activating nuclear factora89I_B. ( 29207194 )
2018
22
O-GalNAcylation of RANTES Improves Its Properties as a Human Immunodeficiency Virus Type 1 Entry Inhibitor. ( 29202246 )
2018
23
Formation of RNA Granule-Derived Capsid Assembly Intermediates Appears To Be Conserved between Human Immunodeficiency Virus Type 1 and the Nonprimate Lentivirus Feline Immunodeficiency Virus. ( 29467316 )
2018
24
Virion-Packaged Pyruvate Kinase Muscle Type 2 Affects Reverse Transcription Efficiency of Human Immunodeficiency Virus Type 1 by Blocking Virion Recruitment of tRNA<sup>Lys3</sup>. ( 29607934 )
2018
25
Detection of IgG3 antibodies specific to the human immunodeficiency virus type 1 (HIV-1) p24 protein as marker for recently acquired infection. ( 29925445 )
2018
26
Adherence and virologic outcomes among treatment-naA^ve veteran patients with human immunodeficiency virus type 1 infection. ( 29480831 )
2018
27
Inhibition of Human Immunodeficiency Virus Type 1 Entry by a Keggin Polyoxometalate. ( 29772712 )
2018
28
Six-helix bundle completion in the distal C-terminal heptad repeat region of gp41 is required for efficient human immunodeficiency virus type 1 infection. ( 29609648 )
2018
29
Lower High-Density Lipoproteins Levels During Human Immunodeficiency Virus Type 1 Infection Are Associated With Increased Inflammatory Markers and Disease Progression. ( 29963050 )
2018
30
Moyamoya syndrome in a pediatric patient with congenital human immunodeficiency virus type 1 infection resulting in intracranial hemorrhage. ( 29138020 )
2018
31
Immunological and virological characteristics of human immunodeficiency virus type 1 superinfection: implications in vaccine design. ( 29170914 )
2017
32
West Nile virus meningitis in a patient with human immunodeficiency virus type 1 infection. ( 28831299 )
2017
33
CRF35-AD as the Main Circulating Genotype of Human Immunodeficiency Virus Type 1 Infection in Iran: A Phylogenetic and Demographic-Based Study. ( 29186704 )
2017
34
Ets-2 Acts As a Transcriptional Repressor of the Human Immunodeficiency Virus Type 1 through Binding to a Repressor-Activator Target Sequence of 5'-LTR. ( 29354130 )
2017
35
Soluble Urokinase Plasminogen Activator Receptor Is a Predictor of Incident Non-AIDS Comorbidity and All-Cause Mortality in Human Immunodeficiency Virus Type 1 Infection. ( 29099961 )
2017
36
Massive Iatrogenic Outbreak of Human Immunodeficiency Virus Type 1 in Rural Cambodia, 2014-2015. ( 29211835 )
2017
37
RbAp48, a novel inhibitory factor that regulates the transcription of human immunodeficiency virus type 1. ( 27222146 )
2016
38
CD235a (Glycophorin-A) Is the Most Predictive Value Among Different Circulating Cellular Microparticles in Thrombocytopenic Human Immunodeficiency Virus Type 1. ( 25716234 )
2016
39
Giant cell myocarditis associated with multiple autoimmune disorders following highly active antiretroviral therapy for human immunodeficiency virus type 1 infection. ( 26780680 )
2016
40
Effect of internal cleavage site mutations in human immunodeficiency virus type 1 capsid protein on its structure and function. ( 27516963 )
2016
41
Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants. ( 26482266 )
2016
42
Genetic analysis of the localization of APOBEC3F to human immunodeficiency virus type 1 virion cores. ( 25505075 )
2015
43
Inhibition of microtubules and dynein rescues human immunodeficiency virus type 1 from owl monkey TRIMCyp-mediated restriction in a cellular context-specific fashion. ( 25502651 )
2015
44
Appearance of drug resistance-associated mutations in human immunodeficiency virus type 1 protease and reverse transcriptase derived from drug-treated Indonesian patients. ( 25348045 )
2015
45
Mycobacterium tuberculosis and Human Immunodeficiency Virus Type 1 Cooperatively Modulate Macrophage Apoptosis via Toll Like Receptor 2 and Calcium Homeostasis. ( 26132135 )
2015
46
ATP generation in a host cell in early-phase infection is increased by upregulation of cytochrome c oxidase activity via the p2 peptide from human immunodeficiency virus type 1 Gag. ( 26577226 )
2015
47
Human Immunodeficiency Virus Type 1 Nef Inhibits Autophagy through Transcription Factor EB Sequestration. ( 26115100 )
2015
48
Azasugar-containing phosphorothioate oligonucleotide (AZPSON) DBM-2198 inhibits human immunodeficiency virus type 1 (HIV-1) replication by blocking HIV-1 gp120 without affecting the V3 region. ( 25623024 )
2015
49
Human immunodeficiency virus type 1 employs the cellular dynein light chain 1 protein for reverse transcription through interaction with its integrase protein. ( 25568209 )
2015
50
Virtual-screening targeting Human Immunodeficiency Virus type 1 integrase-lens epithelium-derived growth factor/p75 interaction for drug development. ( 25230778 )
2015

Variations for Human Immunodeficiency Virus Type 1

ClinVar genetic disease variations for Human Immunodeficiency Virus Type 1:

6
(show all 23)
# Gene Variation Type Significance SNP ID Assembly Location
1 KIR3DL1 KIR3DS, KIR3DS +/- HLA-B Bw4-80ILE undetermined variant Pathogenic
2 CD209 CD209, -336A-G single nucleotide variant protective,risk factor
3 CCR5 NM_000579.3(CCR5): c.554_585del32 (p.Ser185Ilefs) deletion protective,risk factor rs333 GRCh37 Chromosome 3, 46414947: 46414978
4 CCR5 NM_000579.3(CCR5): c.554_585del32 (p.Ser185Ilefs) deletion protective,risk factor rs333 GRCh38 Chromosome 3, 46373456: 46373487
5 CCR5 NM_000579.3(CCR5): c.303T> A (p.Cys101Ter) single nucleotide variant protective rs1800560 GRCh37 Chromosome 3, 46414696: 46414696
6 CCR5 NM_000579.3(CCR5): c.303T> A (p.Cys101Ter) single nucleotide variant protective rs1800560 GRCh38 Chromosome 3, 46373205: 46373205
7 CCR5 NM_000579.3(CCR5): c.-301+246A> G single nucleotide variant protective rs1799987 GRCh37 Chromosome 3, 46411935: 46411935
8 CCR5 NM_000579.3(CCR5): c.-301+246A> G single nucleotide variant protective rs1799987 GRCh38 Chromosome 3, 46370444: 46370444
9 CCR5 NM_000579.3(CCR5): c.180G> T (p.Arg60Ser) single nucleotide variant protective rs1800940 GRCh37 Chromosome 3, 46414573: 46414573
10 CCR5 NM_000579.3(CCR5): c.180G> T (p.Arg60Ser) single nucleotide variant protective rs1800940 GRCh38 Chromosome 3, 46373082: 46373082
11 CCR2 NM_001123041.2(CCR2): c.190G> A (p.Val64Ile) single nucleotide variant protective rs1799864 GRCh37 Chromosome 3, 46399208: 46399208
12 CCR2 NM_001123041.2(CCR2): c.190G> A (p.Val64Ile) single nucleotide variant protective rs1799864 GRCh38 Chromosome 3, 46357717: 46357717
13 CCL11 CCL11, -1385G-A single nucleotide variant protective
14 CXCL12 NM_000609.6(CXCL12): c.266+535G> A single nucleotide variant protective rs387906400 GRCh37 Chromosome 10, 44873550: 44873550
15 CXCL12 NM_000609.6(CXCL12): c.266+535G> A single nucleotide variant protective rs387906400 GRCh38 Chromosome 10, 44378102: 44378102
16 CCL2 CCL2, -2136A-T single nucleotide variant protective
17 CCL2 CCL2, 767C-G single nucleotide variant protective
18 HLA-C NC_000006.12: g.31306603T> C single nucleotide variant risk factor rs9264942 GRCh38 Chromosome 6, 31306603: 31306603
19 HLA-C NC_000006.12: g.31306603T> C single nucleotide variant risk factor rs9264942 GRCh37 Chromosome 6, 31274380: 31274380
20 IL10 NM_000572.2(IL10): c.-627A> C single nucleotide variant protective,risk factor rs1800872 GRCh38 Chromosome 1, 206773062: 206773062
21 IL10 NM_000572.2(IL10): c.-627A> C single nucleotide variant protective,risk factor rs1800872 GRCh37 Chromosome 1, 206946407: 206946407
22 TLR3 NM_003265.2(TLR3): c.1234C> T (p.Leu412Phe) single nucleotide variant protective rs3775291 GRCh37 Chromosome 4, 187004074: 187004074
23 TLR3 NM_003265.2(TLR3): c.1234C> T (p.Leu412Phe) single nucleotide variant protective rs3775291 GRCh38 Chromosome 4, 186082920: 186082920

Copy number variations for Human Immunodeficiency Virus Type 1 from CNVD:

7 (show all 23)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13736 1 1 247249719 Copy number HIV/AIDS
2 74031 13 1 114142980 Copy number HIV/AIDS
3 107129 17 1225928 31649829 Copy number CCL3L3 HIV/AIDS
4 107135 17 1225928 31649843 Copy number CCL3L1 HIV/AIDS
5 107136 17 1225928 31649843 Copy number CCL3L1 HIV/AIDS
6 107137 17 1225928 31649843 Copy number CCL3L1 HIV/AIDS
7 107145 17 1225928 31649843 Segmental duplicatio ns CCL3L1 HIV/AIDS
8 107159 17 1242109 31665953 Copy number CCL4L2 HIV/AIDS
9 110228 17 31562580 31665959 Copy number CCL4L1 HIV/AIDS
10 110279 17 31800000 38100000 Copy number CCL3L1 HIV/AIDS
11 110285 17 31800000 38100000 Copy number CCL4L1 HIV/AIDS
12 110286 17 31800000 38100000 Copy number CCL4L1 HIV/AIDS
13 110848 17 34522267 34625730 Copy number CCL3L1 HIV/AIDS
14 111275 17 35400000 35600000 Copy number CCL3L1 HIV/AIDS
15 112166 17 38100000 38400000 Copy number CCL3L1 HIV/AIDS
16 112167 17 38100000 38400000 Copy number CCL3L1 HIV/AIDS
17 112170 17 38100000 38400000 Loss CCL3L1 HIV/AIDS
18 179925 4 1 191273063 Copy number HIV/AIDS
19 209403 6 2614953 31491069 Copy number MICA HIV/AIDS
20 211349 6 32593131 32665540 Copy number HLA-DRB5 HIV/AIDS
21 212276 6 3674895 32665540 Copy number HLA-DRB1 HIV/AIDS
22 212425 6 3795995 32719407 Copy number HLA-DQA1 HIV/AIDS
23 212441 6 3813334 32742444 Copy number HLA-DQB1 HIV/AIDS

Expression for Human Immunodeficiency Virus Type 1

Search GEO for disease gene expression data for Human Immunodeficiency Virus Type 1.

Pathways for Human Immunodeficiency Virus Type 1

Pathways related to Human Immunodeficiency Virus Type 1 according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
2
Show member pathways
13.8 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
3
Show member pathways
13.58 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
4
Show member pathways
13.45 CCL11 CCL2 CCL3 CCL3L1 CXCL12 IFNG
5
Show member pathways
13.35 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
6
Show member pathways
13.29 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
7
Show member pathways
13.13 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
8
Show member pathways
13.08 CCL11 CCL2 CCL3 CCL3L1 CCR2 CCR5
9
Show member pathways
12.95 CCL2 CCL3 CCL3L1 IFNG IL10 TLR3
10
Show member pathways